Stocks That Hit 52-Week Lows On Friday
During Friday's session, 574 stocks hit new 52-week lows.
Looking Into DarioHealth’s Return On Capital Employed
Benzinga Pro data, DarioHealth (NASDAQ:DRIO) reported Q2 sales of $6.18 million. Earnings fell to a loss of $18.03 million, resulting in a 13.27% decrease from last quarter.
DarioHealth Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, DarioHealth's (NASDAQ:DRIO) reported sales totaled $8.06 million. Despite a 26.27% increase in earnings, the company posted a loss of $15.92 million.
Solera Health Adds DarioHealth to Its Cardiometabolic Network to Offer Hypertension Management Solutions
Solera Health, the premier platform for connecting people seamlessly and easily to proven, personalized health solutions, announces its partnership with DarioHealth, a leading digital therapeutics company revolutionizing how people with chronic conditions manage their health through a user-centric platform.
Dario Health (DRIO) Poised To Inflect Upon Full Launch of National Health Plan
Dario Health (DRIO) Poised to Inflect Upon Full Launch of National Health Plan
- Fundamentals: Company positioned to avoid dilutive financing after recent $50M credit facility with OrbiMed
- Catalysts: Company is guiding for a full launch of a large national insurer, by end of June
Aegis Capital Maintains Buy on DarioHealth, Lowers Price Target to $20
Aegis Capital analyst Nathan Weinstein maintains DarioHealth (NASDAQ:DRIO) with a Buy and lowers the price target from $23 to $20.
Alliance Global Partners Upgrades DarioHealth to Buy
Alliance Global Partners analyst Ben Haynor upgrades DarioHealth (NASDAQ:DRIO) from Neutral to Buy.
90 Biggest Movers From Yesterday
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.
58 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 102.6% to $0.1580 after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered direct offering.